ISRG vs PFE: Which Is the Better Buy?
Side-by-side comparison of Intuitive Surgical, Inc. and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-25.
Intuitive Surgical, Inc. · Healthcare
$399.52
+22.4% upside to fair value
Med Conviction
Grade B
High Quality
VS
Pfizer Inc. · Healthcare
$27.64
+12.0% upside to fair value
Med Conviction
Grade B
QuantHub Verdict
ISRG has more upside to fair value
(+22.4%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ISRG |
PFE |
| Current Price |
$399.52 |
$27.64 |
| Fair Value Estimate |
$488.97 |
$30.94 |
| Upside to Fair Value |
+22.4%
|
+12.0%
|
| Market Cap |
$141.1B |
$157.5B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
30.7x
|
17.4x
|
| Price / Sales |
12.8x
|
2.5x
|
| Price / FCF |
44.0x
|
14.3x
|
| Revenue Growth YoY |
+18.5%
|
+2.6%
|
| Gross Margin |
66.7%
|
71.3%
|
| Operating Margin |
31.3%
|
25.1%
|
| Return on Equity |
17.8%
|
4.9%
|
| Dividend Yield |
0% |
6.22% |
| FCF Yield |
2.28%
|
6.97%
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
Intuitive Surgical develops, produces, and commercializes the da Vinci surgical system and the Ion endoluminal system, along with instruments, accessories, training, and digital solutions that drive a large installed-base and recurring-revenue model. Business quality is high: TTM gross margin of 66.7%, operating margin of 31.3%, net margin of 28.4%, ROE of 17.8%, and revenue growth of 18.5% with …
Pfizer is a global biopharmaceutical leader with a portfolio spanning cardiovascular, oncology, vaccines, immunology, and rare disease, anchored by Eliquis, the Prevnar family, Vyndaqel, Ibrance, Xtandi, Comirnaty, and Paxlovid, and supported by roughly 75,000 employees and a contract manufacturing division. Business quality is medium rather than high: TTM gross margin of 71.3% and TTM operating …
Accumulation Zones
| Metric |
ISRG |
PFE |
| Zone Low |
$366.73 |
$23.21 |
| Zone High |
$415.62 |
$26.30 |
| In Buy Zone? |
Yes
|
No
|